D-PHARMA · Checked.be

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of D-PHARMA is 1.7% (moderate). The 2025 annual accounts show equity of €195k and a net result of €80k. Equity is growing by ~72.3% per year across the filed fiscal years. Its solvency ranks better than 93% of 1432 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 3 annual accounts.

Signals

3 signals · with evidence

Strong solvency vs sector

Solvency is in the sector's strongest quartile: better than 93% of 1432 peers (2025). A comfortable equity buffer.

View the sector comparison

Consistently profitable

Positive net result in the two most recent financial years (2024 and 2025).

View the result trend

Growing equity

Equity grew over 2023-2025. Profits are largely retained rather than distributed.

View the equity trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Filing behaviour

From the deposit records, complete market-wide

Latest accounts filed on time

The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 29-01-2026, 91 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.

The next deadline is still running

The next financial year closes on 30-09-2026 and is due by 30-04-2027. Nothing is late today.

How we compute the deadline

The year end is derived from 3 filed financial years, each closing on 30-09. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 30-09-2025, that is 30-04-2026.

Deadline per financial year

Year closed	Due by	Filed	Variance	Reference
30-09-2025	30-04-2026	29-01-2026	91 d early	2026-00028701
30-09-2024	30-04-2025	28-04-2025	2 d early	2025-00086724
30-09-2023	30-04-2024	29-04-2024	1 d early	2024-00071815

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals

More than 3 years active

Founded in 2023, past the statistically most fragile first 3 years.

No legal incidents

No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone

1.7% Moderate

0%0,5%1,5%4%10%≥25%

Young company +Higher-failure-rate sector +Annual accounts: healthy financial profile −

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated filing)

EBIT marginNot published (abbreviated filing)

Net result€80k-6.4%

Working capital€191k+64.2%

CSV export

Annual accounts & ratios

Source: NBB · 2025

Annual accounts filed on 29-01-2026 with the NBB · fiscal year 2025 · micro

Operating resultNet result

Trajectory (indicative)

Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.

growing Net result: growth of ~33.4%/year over 3 fiscal years, indicative, assuming unchanged policy.

Solid line = filed figures · dashed = extended trend · area = indicative range.

How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison

Fiscal year 2025 · NACE 47, Retail trade · compared within the same schema type (micro schema)

Metric	This company	Sector median	Position in the sector
Solvency	86.1%	23.5%	better than 93% of 1432 sector peers
Net result	€80k	€7k	better than 92% of 1429 sector peers
Equity	€195k	€25k	better than 91% of 1434 sector peers
Gross operating margin	€112k	€34k	better than 79% of 1426 sector peers
Total assets	€226k	€132k	better than 66% of 1433 sector peers

Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.

Sector position over time

Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).

Solvency P93

Stable position over 2023-2025 · n=1432-6722

Net result P92

Stable position over 2023-2025 · n=1429-6703

Equity P91

Improving position over 2023-2025 · n=1434-6737

Gross operating margin P79

Improving position over 2023-2025 · n=1426-6682

Describes the position versus peers, not a forecast.

EBITDA

€111k

-2.0% 23-25

Net profit

€80k

-6.4% 23-25

Cash flow

€81k

-5.8% 23-25

Total assets

€226k

+51.0% 23-25

Equity

€195k

+69.8% 23-25

Working capital

€191k

+64.2% 23-25

Income taxes

€21k

-11.8% 23-25

Debt

€31k

-10.7% 23-25

Show 8 other metrics

Debt ≤ 1y

€31k

-2.6% 23-25

Current ratio

7.10

+53.7% 23-25

Quick ratio

7.10

+53.7% 23-25

Solvency

86.1%

+12.5% 23-25

Debt / equity

0.16

-47.4% 23-25

ROE

41.1%

-44.9% 23-25

ROA

35.4%

-38.0% 23-25

Interest coverage

12.75

-64.0% 23-25

Figures by fiscal year

Highlight YoY changes (±10%)

Fiscal year	2025
Deposit	micro
Revenue	-
EBITDA	€111k
Net profit	€80k
Cash flow	€81k
Staff costs	-
Income taxes	€21k
Dividends	-
Total assets	€226k
Equity	€195k
Debt	€31k
of which ≤ 1y	€31k
of which > 1y	-
Working capital	€191k
Employees (FTE)	-

Ratios (computed)

	2025
Current ratio	7.10
Quick ratio	7.10
Working capital ratio	84.5%
Solvency	86.1%
Debt / equity	0.16
Long-term debt ratio	-
Interest coverage	12.75
Gross margin	-
Net margin	-
ROA	35.4%
ROE	41.1%
EBITDA margin	-
Days sales outstanding	-
Days payable outstanding	-
Inventory turnover	-
Days inventory (DSI)	-

Balance-sheet composition 2025

Assets

Fixed assets €4k · 1.6% Current assets €223k · 98.4%

Equity & liabilities

Equity €195k · 86.1% Debt €31k · 13.9%

Full annual accounts (20 line items)

Filed balance sheet and income statement, exactly as deposited with the NBB.

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€226k
Fixed assets	21/28	€4k
Tangible fixed assets	22/27	€4k
Current assets	29/58	€223k
Amounts receivable within one year	40/41	€59k
Cash & bank	54/58	€128k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€226k
Equity	10/15	€195k
Contributions / capital	10/11	€3k
Accumulated profits (losses)	14	€193k
Amounts payable	17/49	€31k
Amounts payable within one year	42/48	€31k
Trade debts payable within one year	44	€2k
Income statement
Gross operating margin	9900	€112k
Operating result	9901	€110k
Financial charges	65	€9k
Result before taxes	9903	€101k
Income taxes	67/77	€21k
Net result for the period	9904	€80k
Result to be appropriated	9905	€80k

This table shows the latest fiscal year. 2 prior years, with figures and ratios, belong to a paid plan. See plans →

Ratios computed by Checked.

Health barometer

FY 2025 · computed

93 / 100 Excellent

050100

Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.

See plans →

Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.

Structure & network

Locations & real estate

Registered office

from the Crossroads Bank

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Meeslaan 142930 Brasschaat

Establishment units

1 location

D-PHARMA

Meeslaan 14, 2930 BrasschaatDetailhandel in farmaceutische producten

since 20232.348.067.914

Physical sites registered in the Crossroads Bank for Enterprises (CBE).

Parcels1

Ground area366 m²

Buildings1

Building footprint88 m²

Volume (LiDAR)624 m³

Tallest building9.5 m · ±3 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
11324D0306/00Z005	Flanders	366 m²	1 · 88 m²	9.5 m · 3 fl.

Methodology

via registered seat: 1

1 of 1 parcels with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgian State Gazette · acts

No structured acts for this company yet

That means one of two things: the company has published no company deeds, or its deeds are still queued for reading. The insolvency signals above come from a separate source; the KBO register is the second source and appears as the legal situation on this page.